Newly published data from a phase 3 clinical study suggests that the recombinant factor VIIa bypassing agent (BPA) eptacog beta was used to safely and effectively treat and control bleeding in children with hemophilia A or B with inhibitors, 12…
Join your community for an evening full of fun at the Free Way Bowl after attending the Outreach Clinic with the HTC. Enjoy some good food, great conversations, and memories to last a lifetime! There will be all you can eat salad, pizza, soda, and…
Men 18+ living with or caring for someone with a bleeding disorder are invited to join us for a fun night out, including a brewery tour and dinner, at Breckenridge Brewery in Littleton, CO!
Learn More
The issue of poor bone health represents a significant public health concern in the U.S. population, including for individuals with hemophilia who are at increased risk for low bone mineral density (BMD) and bone fractures. While low BMD in…
Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors
Speaker(s): Dr. Katharina Holstein
NHF's Wednesday Webinars are a free education series…
Lived experiences and barriers to care for men with hemophilia
Speaker(s): Dr. Michelle Sholzberg and Dr. Sumedha Arya
NHF's Wednesday Webinars are a free education series open to providers and community members…
Factor product utilization and health outcomes in patients with hemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes
Speaker(s): Dr. Linda Sun
NHF's…
Sickle Cell Disease & Red Blood Cell Transfusion
Speaker(s): Dr. Sally Campbell Lee
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…